Emcure Pharmaceuticals Reports 64% Surge in Q4 Profit, Announces Dividend May 23, 2025
Emcure Pharmaceuticals posted a 64% increase in Q4 net profit to Rs 189.00 crore, with revenue rising to Rs 2,116.00 crore. Profit margins expanded to 19%. The company announced a dividend of Rs 3.00 per share and plans to incorporate a wholly-owned subsidiary, Emcure Generics Pvt. Year-over-year, revenue grew by 18.93%, net profit by 62.98%, EBITDA by 22.76%, and EPS increased to Rs 9.97, up 56.76%.
Emcure Pharmaceuticals Reports 64% Surge in Q4 Profit, Stock Rises 8% May 22, 2025
Emcure Pharmaceuticals Receives Positive USFDA Inspection Report for API Facility Apr 21, 2025
Emcure Pharmaceuticals Receives USFDA Approval for API Facility Apr 19, 2025
Emcure's European Arm Tillomed Expands Portfolio with £19.7 Million Acquisition from Manx Apr 04, 2025
More news about Emcure Pharmaceuticals
01Apr 25
Emcure Pharmaceuticals' Subsidiary Inks Deal to Revolutionize Skin Tightening Market in India
Emcure Pharmaceuticals' subsidiary, Emcutix Biopharmaceuticals, has signed an exclusive agreement with Italian firm WiQo to import and distribute 'PRX-PLUS', an innovative skin tightening product, in India. PRX-PLUS offers immediate, non-invasive skin tightening without injections or recovery time. The Indian dermatology market, valued at $1.80 billion, is expected to grow at 11-12%. This partnership aims to introduce advanced skincare solutions and strengthen Emcure's position in the expanding dermatology sector.
01Apr 25
Gennova Biopharmaceuticals Secures $13.38 Million for AI-Enhanced Nipah Virus Vaccine Development
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has expanded its collaboration with CEPI, receiving up to $13.38 million in funding to develop a Nipah virus vaccine. The project will use Gennova's self-amplifying mRNA technology and AI capabilities from Houston Methodist Research Institute. Nipah virus, with a mortality rate of up to 75%, poses a threat to over 2 billion people globally. The partnership aims to ensure equitable access to the developed vaccines and could serve as a model for rapid response to future epidemic threats. Preclinical and phase 1 trials will be conducted in India.
01Apr 25
Emcure Pharmaceuticals' Subsidiary Inks Exclusive Deal with Italian Skincare Brand WIQO
Emcure Pharmaceuticals' subsidiary, Emcutix, has entered an exclusive licensing partnership with Italian derma-cosmetic brand WIQO to introduce innovative skincare solutions in India. This strategic move aims to capitalize on the growing Indian skincare market. Simultaneously, another Emcure subsidiary, Gennova Biopharmaceuticals, is advancing in vaccine development, securing $13.38 million from CEPI to develop a Nipah virus vaccine using saRNA technology.
10Mar 25
Emcure Pharmaceuticals Expands into Daily Supplements Market, Partners with Vidya Balan
Emcure Pharmaceuticals has expanded its Arth range to enter the daily supplements market, focusing on women's health and wellness. The company has partnered with Bollywood actor Vidya Balan as brand ambassador to promote key products including intimate care, sleep support gummies, and brain fog aid. This strategic move aims to address overlooked health concerns and destigmatize women's health issues, potentially opening new revenue streams in the growing wellness sector.
27Feb 25
Emcure Pharmaceuticals Receives Two Observations from USFDA Inspection at API Facility
Emcure Pharmaceuticals' API manufacturing facility in Maharashtra, India, underwent a USFDA inspection from February 19-25, 2025, resulting in two Form 483 observations. The company has committed to addressing these observations comprehensively and responding within the stipulated timeframe. The specific details of the observations were not disclosed in the regulatory filing.
26Feb 25
Emcure Pharmaceuticals Receives Two Observations in FDA Inspection of Pune API Plant
Emcure Pharmaceuticals' API manufacturing facility in Pune underwent a USFDA inspection from February 19-25, 2025, resulting in two observations on Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. The inspection was conducted at the M.I.D.C., Kurkumbh, Taluka - Daund, Pune facility, focusing on current Good Manufacturing Practices (cGMP).